Corvus Pharmaceuticals, Inc. (CRVS) Earnings Call Transcript & Summary
August 6, 2026
Earnings Call Speaker Segments
Executive
executiveThanks so much, Operator, and good afternoon to all of you. We appreciate your joining us for Corvus Pharmaceuticals' second quarter 2026 Business Update and Financial Results Conference Call. Here to talk through the results and business updates are Richard Miller, our Chief Executive Officer, Lace Lee, our Chief Financial Officer, Jeff Arcarra, our Chief Business Officer, and Ben Jones, our Senior Vice President of Pharmaceutical Development. Our executive team will kick things off with some prepared remarks, and after that we'll take questions. I want to remind everybody that what management says today, along with responses to questions, will contain forward looking statements. Such forward looking statements rest on estimates and assumptions as of today. They also carry risks and uncertainties that could lead actual results to differ materially from what those statements express or imply, including the risks and uncertainties laid out in Corvus' annual report, its quarterly report on Form 10-Q for the quarter ended June 30, 2026, and other filings the company makes with the SEC from time to time. The The company undertakes no obligation to publicly update or revise any forward-looking statements except as required by law.
Leiv Lea
executiveOkay, I'll hand things over now to Leif Lee. Leif? Thanks, Zach. I'll start with a quick look at our financials for the second quarter of 2026, and after that I'll pass things to Richard for an update on the business. R&D expenses came to $16 million during the second quarter of 2026, which compares with $7.9 million in the same period of 2025. The rise in R&D spending was driven mainly by greater clinical trial costs tied to developing socalitinib, along with higher personnel costs. Our net loss in the second quarter of 2026 reached $18 million, versus a net loss of $8 million during the same period in 2025. Within the net loss for both the second quarter of 2026 and 2025 were non-cash losses of $0.7 million and $0.4 million, respectively, stemming from Corvus's equity method investment in Angel Pharmaceuticals, plus a non-cash gain of $2 million in the second quarter of 2025 tied to a change in fair value of the company's warrant liability. Total stock compensation expense for the three months ended June 30th, 2026 came to $2.6 million, compared with $1.3 million in the same period of 2025. At June 30th, 2026, Corvus held cash, cash equivalents and marketable securities of $215.2 million, versus $56.8 million at December 31st, 2025. Cash at June 30th, 2026 included roughly $189.4 million in net proceeds from a follow-on offering that closed in Q1. In addition, as we announced on June 9th, 2026, Corvus put $5 million into a $13.5 million financing that angel pharmaceuticals completed during the second quarter of twenty twenty six. Given our cash position at June 30th, 2026, and our current plans, we anticipate that our cash will fund operations into the second quarter of 2028. I'll now hand the call to Richard, who will talk about our clinical progress and go into more detail on our strategy and plans.
Richard Miller
executiveThank you, Leif, and good afternoon, everyone. I appreciate all of you taking the time to join today's update call. Our primary focus right now is soquelitinib, which is our first-in-class selective ITK inhibitor. Most of our energy is going toward boosting patient enrollment and carrying out our clinical trials so we can hit the upcoming milestones for soquelitinib's two main opportunities: the phase three program in peripheral T cell lymphoma, or PTCL, and the phase two program in atopic dermatitis. At the same time, we're continuing to push soquelitinib's development forward across a wide range of medical areas, including near-term plans to launch trials in hidradenitis superativa and asthma, plus the ongoing asthma trial at the NIAID. There's mounting evidence from both clinical studies and preclinical research supporting soquelitinib's wide-ranging promise, thanks to how it works in a novel way and its ability to reset or rebalance the immune system. As we keep advancing soquelitinib through development, Corvus is positioned to produce important data readouts and pipeline-related milestones during the next twelve months. First, a brief update on our phase three study in relapsed refractory disease. That trial is built to enroll 150 patients, randomized one to one between and standard of care chemotherapy. With the Linda stat or. The main endpoint is progression-free survival, or PFS, which with the treatment options available today has a median of about three months. Sign-ups are coming in right in line with what we anticipated, and the upcoming checkpoint is a futility review, which gets triggered after a set count of PFS events has occurred. Based on how things look right now, our expectation is that this interim look for futility will take place during Q1 of 2027. An independent data monitoring committee is the group that will conduct this utility analysis, and using whatever safety and efficacy information exists at that moment, they'll determine if the trial moves forward or gets halted because of futility. Nothing regarding safety or efficacy will be released to the public at that point. We remain enthusiastic about soquelitinib's potential as a novel therapeutic alternative for patients battling relapsed refractory PTCL, particularly given how challenging existing treatment approaches are—not one of them holds full approval for this indication. I'd also like to mention that findings from our phase one study have been accepted for publication in Blood, the peer-reviewed medical journal of the American Society of Hematology; those results should come out later this year, providing a key summary of soquelitinib's mechanism of action, its rationale, and data gathered from the Phase I trial. A portion of these data was shared at last year's ASH meeting. Turning to atopic dermatitis, which is another indication we're prioritizing highly for soquelitinib, we continue to feel a lot of enthusiasm about both the results we've seen so far and the direction we're taking in this area. In Q2, at the annual meeting of the Society for Investigative Dermatology, or SID, we shared the complete dataset from the randomized, blinded, placebo-controlled phase one study of soquelitinib in people suffering from moderate to severe atopic dermatitis. What came out of that was a safety profile plus encouraging efficacy, since 75% of the patients in cohort four—the ones described as "so-called in their"—achieved EASI 75, compared with 20% of the placebo group. In this trial, cohort four represented both the largest dose and the most extended treatment duration that was examined, and it included 24 subjects assigned randomly in a 1:1 ratio to receive either soqualitinib or matching placebo on a 200-milligram, twice-daily schedule for 56 days, which is 8 weeks. In addition to that strong EZ75 result, among the so-called it patients within cohort four, 25% achieved EZ90 while 33% achieved an IgA0 or 1. No one receiving placebo got to EZ90 or IgA0. Notably, socolitinib demonstrated efficacy in individuals who had undergone prior systemic therapy, and a number of those patients were confirmed to be treatment resistant to such systemic therapies. The data also revealed an efficacy trend that depended on dose, together with added clinical benefit derived from a longer course of treatment. One thing that really stood out to us was the extended therapeutic benefit that continued beyond the treatment window, without any indication of the disease coming back. Rebound has been observed with other therapies, including dupilumab, JAK inhibitors, and STAT6 degraders and inhibitors. Given work from Corvus and other researchers demonstrating that blocking ITK enhances T regulatory function, the sustained activity of soqualitinib did not catch us off guard. During the SID presentations, we presented strong evidence connecting Treg induction with lasting clinical responses. If upcoming trials bear this out, these results could pave the way for a new paradigm in treating autoimmunity — one focused on resetting or rebalancing the immune system. Turning to safety, we found nothing of concern. There were no severe or serious adverse events, and no notable laboratory abnormalities emerged. Conjunctivitis didn't come up at all, and because this is just a standard medication, injection site issues also didn't occur. When the placebo arm was measured against the active arms, adverse events came out the same. Everything here lines up with our experience in what are referred to as lymphoma patients, a number of whom have stayed on the drug without interruption for more than two years. Taking into account how it works, which is novel, the fact that it's taken by mouth, and the safety and efficacy results gathered to date, our view is that soquitinib has the potential to become a top-tier atopic dermatitis treatment, possibly playing an important part either in first-line use or in addressing relapsed refractory disease. We intend to advance SOPL and NIP as quickly as possible along the standard development route, in much the same way other systemic atopic dermatitis treatments have already gained approval. That covers employing the NIP-A1-A2 therapy for atopic dermatitis. It also covers our phase two study, the Sierra one trial, which is enrolling patients right now, and the phase three trials that normally follow. For those trials, the primary endpoint will rest on EASY score and IGA score at 12 or 16 weeks of therapy versus placebo. What we want is to bring Soquel et Nib to patients at the earliest opportunity, and afterward to expand the clinical evidence and the label by way of post-marketing studies that examine some of its more distinctive characteristics. We intend for the Phase 2 Sierra study to randomize about 200 individuals suffering from moderate to severe atopic dermatitis who have not responded to at least one earlier topical or systemic treatment. The design is double-blind and randomized, featuring four groups of 50 subjects apiece, testing soqualitinib at 200 milligrams given once daily, 200 milligrams given twice daily, and 400 milligrams given once daily, plus a placebo arm. Treatment lasts 12 weeks, followed by a 90-day observation window during which no drug is administered. As noted, the main goal is a decrease in the mean easy score at the 12-week mark relative to placebo. We have opted against any OLE, or open label extension, since we expect remissions to be durable and do not wish to cloud that picture by giving more treatment. In our case, the OLE is simply no treatment. Site activations and enrollment are proceeding as anticipated, and we expect to finish enrolling in early 2027, with top line data arriving in the third quarter of 2027. At the same time, we are collaborating closely with Angel Pharmaceuticals, our partner in China, on their Phase 1B2 study of soqualitinib for moderate to severe atopic dermatitis. That ANGEL trial's design mirrors our Phase 2 trial. It is blinded and placebo-controlled, and it is assessing a 12-week course of treatment plus a 90-day follow-up across a comparable span of so-called nebdoses.
Richard Miller
executiveCohort 1 has 24 patients who were randomly assigned in equal numbers to soqualitinib at 100 milligrams twice daily, to milligrams once daily, or to placebo. Cohort two is going to have 24 patients split evenly among soqualitinib at 200 milligrams twice daily, 400 milligrams once daily, or placebo. Based on what comes out of these 48 patients across cohorts 1 and 2, another 60 to 90 patients are expected to be brought into the phase 2 portion of the study. The trial is currently open at a number of top dermatology centers in China that have taken part in numerous global registration trials. We expect ANGEL to finish enrolling patients for the first cohort in September, and results from that first cohort should be on hand before the close of 2026. The soqualitinib doses being tested in this cohort match the lower dose level that was studied in our phase one trial, 200 milligram total per day, given either as a 100 milligram tablet twice daily or as 200 milligrams once daily. The treatment duration, though, is much longer at 12 weeks versus the four-week period that was studied for these doses in our Phase I trial. Keep in mind, we saw evidence of efficacy at these lower doses in our phase one trial after four weeks of therapy. Angel is testing these doses in a 12-week dosing regimen. We expect results from cohort two to be available in the second quarter of 2027. So to restate the ANGEL timelines, we expect them to finish enrollment of the first cohort in September, results from this cohort by the end of this year, and results from the second cohort in Q2 2027. With the ANGEL data, along with our own data that will be produced during 2027, we could be positioned to launch a Phase 3 trial by the end of 2027. Besides supplying clinical data that supports the value of socalinib in atopic dermatitis, there is a second important strategic element to the ANGEL trial. It is commonly reported in the literature that Asian patients with atopic dermatitis have a larger component of TH17 disease and and respond less well to IL-4 and IL-13 targeted treatments like dupilumab, which is designed to treat TH2 disease. and does not respond to TH7, and does not affect TH17. Given the mechanism of action with ITK inhibition, which lowers both Th2 and Th17 cell function and their downstream cytokines, we think this positions so well for this population. Finding results in these types of patients may serve to broaden and confirm the potential utility in TH17 diseases. One example of how important ANGEL is to Corvus is our participation in ANGEL's recent $13.5 million financing. Harvest is a founder of Angel and continues to be its largest shareholder with $5 million invested in this new financing. This money is expected to back Angel's ongoing phase 1b, 2 study of socazolimab for atopic dermatitis. It will also support a fresh phase 2 study of socazolimab in asthma, which should kick off in early 2027. Our view is that Corvus stands to gain from both studies, since they will add to the overall body of data for soqualitinib across these indications and boost the chance for ITK inhibition in China's sizable inflammation and immunology market. I serve as CEO and Chairman of Angel, and I have to say that working alongside the highly skilled team in China has been both an honor and a pleasure. Back in the U.S., Corvus is still on schedule to launch our own Phase II asthma study before this year ends, plus a Phase Ib proof-of-concept study in patients with HS, meaning hidradenitis suppurativa. Expanding the soqualitinib pipeline into these indications fits with the biology behind ITK inhibition. We began with TH2 cells in T cell lymphoma, then shifted to atopic dermatitis, which is mainly driven by TH2 cells. From there, we are now turning to Hidroadenitis superativa, which is mainly driven by TH17 cells, and after that to asthma, which is mainly driven by TH2 cells. TH2 cells, though in certain types the disease is dominated by TH17 cells. There is a key strategy behind our clinical programs: each one is built not just to tackle a meaningful clinical indication, but also to generate data that backs soqualitinib's mechanism of action and its possible usefulness across a range of underlying disease drivers. For the phase 1B, we presently expect enrollment of as many as 25 patients with moderate to severe disease. No placebo arm will be used. Every patient will get the identical dose of socolitinib over 12 weeks, 200 milligrams BID. Beyond tracking safety and the standard hydradenitis superativa clinical response score, we also intend to build in intensive monitoring of skin and blood biomarkers, searching for TH17 effects. We plan to begin this study in September. Socalitinib's possible broad usefulness is a major consideration in shaping our planned asthma study. We aim to enroll both the allergic or eosinophilic form and the non-allergic form of asthma. These may also be called T2 and non-T2. The majority of asthma drugs and most clinical trials target only the allergic T2 patients. We aim to enroll both pipes, based on our mechanism of action, which we think will cover both T2 and non-T2 disease. Roughly 40% to 50% of asthma patients have the non-T2 type. That is a very substantial share of asthma patients; it doubles the potential patient population. An interim analysis will be part of the trial design, letting us stop a disease type, whether T2 or non-T2, if futility appears. We stay enthusiastic about socaladnib's potential to modulate multiple key cellular functions that no approved or in-development biologic therapy currently targets, all through an oral tablet. During the SID conference, two Stanford faculty members, Professors Chu and Saren, shared fresh immunology and biomarker findings. Those findings demonstrated how blocking ITK through socolitinib might boost the persistence of Treg cells and act on several inflammatory pathways at once. Such results lend support to the idea that this agent—referred to as adnib—could reset or rebalance the immune response, letting it treat a variety of autoimmune and inflammatory conditions. Looking further ahead, this also opens up the quite fascinating possibility of achieving drug-free remissions, something the field has pursued for a long time. To wrap up, our belief in soqualitinib keeps strengthening, and we are moving well on our main objectives as we work to seize the chance to assist a wide array of patients through ITK inhibition. Across the rest of this year, our attention goes first to boosting enrollment in what we call our phase three registration study along with our phase two a topic dermatitis study. Next, we are working hand in hand with our China partner, angel pharmaceuticals, on their phase one, B, two, a topic. like dermatitis study, with results from the initial cohort expected before the year closes and results from the subsequent cohort in the second quarter of 27. Third, we aim to push forward the wider soqualitinib prospect by launching trials in asthma and and Hidradenitis superativa before this year ends.
Richard Miller
executiveOnce these milestones are reached, we think recognition will grow regarding what inhibiting ITK and modulating the immune system might accomplish, and that could open the door to improved, novel treatments for cancers, fibrotic conditions, autoimmune disorders, and inflammatory diseases. At this point, I'll hand things over to the operator so we can move into the question-and-answer session.
Jeff Jones
analystHey everyone, is my audio coming through? Yeah, you sound okay. Good. Hello, Richard. Also, congratulations on the strides made and the ongoing strides for this program. Regarding drug-free remissions, has there been any dialogue with the agency concerning the possibility of drug-free remissions, plus how a label claim would be pursued and what the shape of such a study design might be?
Richard Miller
executiveJeff, at present everything we're undertaking uses a simple design. We pit what we call adnip against placebo. easy scores, easy 75s, IGAs at 12 or 16 weeks. Identical to everyone else. That's the requirement. Those constitute our protocols. As for what happens during remission periods or drug-free periods, just as others do, dupilumab, JAK inhibitors, they keep treating certain patients, or some who received placebo, to figure out whether disease rebound occurred, and nearly always it does. Consequently, they concluded maintenance therapies were needed for those diseases, yet those weren't included in the initial approvals. So doing that isn't required. We believe it matters greatly if we achieve sustained remissions that don't call for a drug, which represents, in my view, a tremendous opportunity and distinctive edge for what we call in it, though that isn't part of the regulatory strategy. At a later point, if you wish to be able to retreat patients, then naturally, additional trials, you'd run additional trials to verify that.
Jeff Jones
analystIs that clear? Wonderful. Yeah, that's completely clear; and then I have just one more thing to ask. Clearly, the highest dose currently seems to be 200 mg BID. Is any effort being made by you folks to investigate extended release formulations? Yes.
Richard Miller
executiveWell, within the company we do have efforts underway exploring alternative formulations. We've also got efforts at the company examining quite a lot of activity related to other ITK inhibitors, other chemical structures, and so forth. My guess is that we'll probably wind up with a schedule involving once-a-day dosing, since I believe when we treat patients beyond four weeks, once-a-day dosing will deliver quite adequate efficacy; at present, we're examining a range of regimens. As you're aware, in our cancer study, we escalated to 600 milligrams. Yet we know that 200 milligrams given as a single dose will fully saturate the ITK target.
Jeff Jones
analystMany thanks, Richard, and once more, congratulations on everything that's been accomplished. Richard Wolitski, thank you.
Analyst
analystHello, Sam here, filling in for Greg. We appreciate you fielding our questions. Nice work on the advances, team. Perhaps regarding the PTCL, it appears the possible interim readout slipped by one quarter. I'm simply wondering what went into those deliberations, and do you still expect the phase three data before next year wraps up, or has that shifted toward being a 2028 matter now? Thanks.
Richard Miller
executiveOur expectation is final data in late 27, just as we said from the start. The interim analysis, naturally, gets projected according to events. Consequently, pinpointing precisely when those happen is difficult, and beyond that, it hinges on how many events there are, in line with our statistical plan and what we agreed upon with FDA. Given event rates, our current projection is early in 2027, and that might shift somewhat, subject to how many events take place.
Analyst
analystHey there, Eric here, filling in for Paul. Appreciate you taking my question. Just a quick one. Is it possible for you to incorporate the Angel Partner data into the safety database for additional FDA submissions? Also, are you expecting somewhat improved efficacy among Chinese patients for AD? Or what's your perspective? Could you give us some insight into how you anticipate that playing out?
Richard Miller
executiveRegarding what might shift in the Chinese population? Absolutely, we're able to include the Chinese safety and efficacy information in our regulatory submissions, and the reverse is true too. They're able to incorporate our data into their submissions. That's among the reasons we kicked off this partnership back several years ago. The concept was to speed things up and broaden our abilities, plus tap into the Chinese population, regulatory bodies, and clinical trial infrastructure, all of that. So indeed, the data is shareable. On the second part of what you asked, do I anticipate it being—I anticipate comparable results from ANGEL. It's a separate study. It's a completely distinct clinical trial conducted at a different time at different sites. Tough to forecast precisely. In theory, I believe we might outperform placebo by a larger margin since we have this combined impact on TH17 TH1. So, someone could anticipate, say, relative to other therapies, a superior outcome; but you know, it's tough—it will be tough to draw comparisons between trials and across the Pacific Ocean. However, the Chinese trials are underway at, I believe there are roughly ten sites currently. They're excellent, well-recognized, academic, sizable hospital and dermatology clinics; they're frequently locations for big pharma and numerous other treatments in dermatology and atopic dermatitis specifically; so we feel quite confident about the quality, and the insights we'll obtain from there. All right. Really useful. Thank you.
Cha Cha Yang
analystHello, I'm Chacha, filling in for Roger. I appreciate you taking my question. There are two things I'd like to ask. First, could you elaborate on the reasoning for running a 12-week study instead of a 16-week one for AD in your Phase II? And for my second one, perhaps you already addressed it and I missed it, but could you share additional details regarding the trial design along with some baseline characteristics for the HS and asthma studies? Thank you.
Richard Miller
executiveRegarding duration, we examined a period of four weeks. At first we considered dosing for four weeks, after that moved to eight, and currently we are conducting dosing across 12 weeks. At four weeks with 200 milligrams BID, we observed really strong efficacy; at eight weeks we also observed really strong efficacy, with curves that kept declining. So we'll examine the twelve-week data we obtain, both from angel and from what we're doing in our phase two, and then we'll decide how to proceed from there. Um. I realize many people ask whether 16 weeks is some kind of magic number. It is not. From our perspective, if strong efficacy can be achieved using a shorter dosing schedule, what would be the point of not doing so? So down the road, should we find that the curves keep declining, we will move to 16 weeks. However, at this moment I see no justification for that. Some of the dermatology experts we work with have said to us that, wow, your four-week results match what is typically observed at 16 weeks. Also, I'd suggest going back to review the published literature. on dupilumab and JAK inhibitors, and you will find treatment durations of 12 and 16 weeks. And what do you know? Those curves flatten out somewhere around six or eight weeks; so the bulk of efficacy in those 12 and 16 week regimens — go back and examine the easy curves. The majority of efficacy appears within the initial couple of months. beyond that, the shifts are actually quite minor. Alright, was there another portion to your question?.
Cha Cha Yang
analystCould you say that again? Alright. Specifically regarding how the HSN study is designed and what the baseline characteristics look like.
Richard Miller
executiveFor moderate to severe HS and moderate to severe asthma — the asthma study is the one really worth discussing. So, as everyone knows, the majority of trials are allergic or T2. An eosinophil count of 300, or 150 and above, or above 150 — that is shifting nowadays — has often been used as an entry criterion; we permit either. T2 and non-T2. In other words, we'll enroll patients with eosinophils above 150 and below 150. Now, regarding eosinophil count, we've examined our AD data. Those above 150 and those below — where efficacy is concerned, we observe essentially the same efficacy across both groups. So, again, I believe we're beginning now to consider what possible benefits our novel mechanism of action might offer. With non-T2 asthma, if you examine their lungs, TH2 cells aren't visible. You see plenty of neutrophils, you see other inflammatory cells that TH17 cells bring about. TH17 cells produce neutrophil attractants, such as GM-CSF and similar substances. And so, in our animal models, we've observed that we can influence that. And naturally, mechanistically, we know we're blocking Th17 differentiation; so that's the primary eligibility criterion. There is the account. Of course, we also consider other things, but that is the main one.
Analyst
analystHello there, this is Rubin. I have one thing I want to ask regarding the asthma program you're running; you mentioned that T2 as well as non-T2 asthma are both being addressed. Could you walk me through the mechanism behind why you believe the sequelae occur?
Richard Miller
executiveSure, so with T2 — T2, naturally, gets its name since it is mediated by TH2; and naturally, like we've said before, it plays a highly significant role within T2. Clearly, we will prevent Th2 cells from differentiating along with the cytokines that come out of that, so the Th2 side is fairly self-evident. When it comes to non-T2, that's Th17. What you predominantly observe are Th17 cells plus additional inflammatory cells, though those additional inflammatory cells get induced by the Th17 cells themselves. Given that we prevent activated Th2 and Th17 cells from differentiating, our expectation would be to observe activity across both T2 and non-T2. Then there is one more key cell type playing a role in each of these, T2 and non-T2, known as the innate lymphoid cell type 2, which has the highest expression of iodine of any lymphocyte at all, and we are aware that we suppress it quite effectively too; so plenty of grounds exist to believe we'd have an impact on non-T2, and this gives us a fantastic chance to put that to the test in the clinic; and naturally, it offers a distinct edge relative to other asthma therapies.
Analyst
analystThanks a lot for fielding our questions. I've got another one about the asthma program — more precisely, the Phase 2 program with Planned Agile Pharma. Could you share a bit more on what the study design might look like, and also how what we learn from it is going to feed into the global program? Thank you.
Richard Miller
executiveWas that — are you referring to ANGEL-AD, or? Oh, okay, I don't think I'm set to answer that yet. Right, the ANGEL-ASMA study. So yes, as things stand we intend for the ANGEL trial to be essentially the same as ours. Right now our plan is to conduct 2 phase 2 trials that are identical. That means the protocols would be basically the same in both locations, though each would be run on its own.
Analyst
analystGreat; regarding those protocols, could you assist us in gaining a clearer picture of the decision tree concerning... the capacity to eliminate either T2 or non-T2? Is there a specific quantity of patients who will undergo that evaluation? And yes, just a bit more detail on that aspect of the study design. Thank you.
Richard Miller
executiveSo, yes, we'll examine actually, our approach will be grounded in the proportion of trial patients who have been treated and at that point, review the data and we've composed that section of it kind of using broad criteria because the success in non T2 differs from T2. The efficacy bar is not as high. It's more difficult to treat; so we possess general guidelines now once a certain quantity of patients have been treated. If we fail to achieve a specific threshold in the T2 or the non T2. to we can eliminate either of those or we can pull all of them. But, and the rationale behind us doing that is because let's just say it's ineffective in the non-T2. We would not want to keep going and dilute out the effect, let's say, positive effect on the T2.
Richard Miller
executiveOperator, I'd like to hand things back over to Zach for some final thoughts. Okay. Thanks, operator. To start, I appreciate all of you being with us today. It's quite busy around Corvus right now. The team — and I should mention, they bring substantial experience running randomized trials — is putting in a great deal of effort at the moment. They're hitting the objectives I laid out. We're eager to keep everyone informed as we progress through the remainder of this year and into next year. Thanks so much.
Operator
operatorThat wraps up the conference call for today, everyone. We appreciate all of you joining us. You're free to hang up at this point. Please note this live transcript is produced automatically, with no human involvement or oversight.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Corvus Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Corvus Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Corvus Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.